Platelet Associated u-PA Up-regulates u-PA Synthesis by Endothelial Cells

Summary

Adhesion of platelets to endothelium has been shown to induce important changes in endothelial properties. In this study, we examined the effect of platelet-endothelial cell interactions on the expression of urokinase-type plasminogen activator (u-PA) by human microvascular endothelial cells. After incubation of endothelial cells with platelets, a dose-dependent increase in the expression of u-PA Ag was observed and reached a plateau for a ratio of 300 platelets per endothelial cells. The u-PA Ag upregulation resulted from an increase in u-PA mRNA that originated from a synthesis by endothelial cells since no u-PA mRNA was detected in platelets. The platelet-induced u-PA synthesis was inhibited when the endothelial cells were pre-treated with phospholipase C to remove the u-PA receptor, or when the platelets were incubated with an antibody that blocks the binding of u-PA to u-PAR. Taken together, these data indicate that u-PA present on the platelet surface interacts with u-PAR on the endothelial cells and induces the u-PA synthesis. This mechanism may represent a physiological control of platelet-mediated intravascular fibrin deposition.

Keywords

Urokinase - platelets - endothelial cells - urokinase-plasminogen receptor

• References

• 1 Blasi F, Vassalli JD, Dano K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 1987; 104: 801-4.
• 2 Vassali J-D, Sappino A-D, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-72.
• 3 Binder BR. Influence of urokinase on cell proliferation and invasion. Blood Coagul Fibrinolysis 1990; 01: 717-20.
• 4 Dano K, Andreasen PA, Grondahl HJ, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
• 5 Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol 1988; 04: 93-126.
• 6 Blasi F. Surface receptors for urokinase plasminogen activator. Fibrinolysis 1988; 02: 73-84.
• 7 Yamamoto K, Loskutoff DJ. Fibrin deposition in tissue from endotoxintreated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest 1996; 97: 2440-51.
• 8 Carmeliet PC, Schoonjans L, Kiecken L, Ream B, Degen J, Bronson R, DeVos R, van den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-24.
• 9 Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest 1984; 73: 1731-9.
• 10 Bugge TH, Flick MJ, Danton MJS. et al Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996; 93: 5899-904.
• 11 Camoin L, Pannell R, Anfosso F, Lefevre JP, Sampol J, Gurewich V, Dignat-George F. Evidence for the expression of urokinase-type plasminogen activator by human venous EC in vivo. Thromb Haemost 1998; 80: 961-7.
• 12 Van Hinsberg VWM, van Den Berg EA, Fiers W, Dooijewaard G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human EC. Blood 1990; 75: 1991-8.
• 13 Wotja J, Gallichio M, Zoellner H, Filonzi EL, Hamilton JA, Mc Grath K. Interleulin-4 stimulates expression of urokinase type plasminogen activator in cultured human foreskin microvascular EC. Blood 1993; 81: 3285-92.
• 14 Saksela O, Moscatelli D, Rifkin DB. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary EC. J Cell Biol 1987; 105: 957-64.
• 15 Olofosson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitaloi K, Eriksson U. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. PNAS 1998; 95: 11709-14.
• 16 Li C, Zhang J, Jiang Y, Gurewich V, Shen Y, Liu JN. Urokinase-type plasminogen activator upregulates its own expression by endothelial cells and monocytes via the u-PAR pathway. Thromb Res 2001; 103: 221-32.
• 17 Menashi S, Soria C, Soria J, Thomaidis A, Legrand Y. Modulation of EC fibrinolytic activity by platelets. Thromb Haemost 1991; 65: 77-81.
• 18 Gurewich V, Johnstone M, Loza JP, Pannell R. Pro-urokinase and prekallikrein are both associated with platelets: implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEBS Lett 1993; 318: 317-21.
• 19 Park S, Karker LA, Marzec UM, Levin EG. Demonstration of single chain urokinase-type plasminogen activator on human platelet membrane. Blood 1989; 73: 1421-5.
• 20 Jiang Y, Pannell R, Liu JN, Gurewich V. Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes. Blood 1996; 87: 2775-81.
• 21 Gawaz M, Neumann FJ, Dickfeld T, Reininger A, Adelsberger H, Gebhardt A, Schomig A. Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of EC: implications for reperfusion in acute myocardial infarction. Circulation 1997; 96: 1809-14.
• 22 Zhou L, Stordeur P, deLavareille A, Thielemans K, Capel P, Goldman M, Pradier O. CD40 engagement on EC promotes tissue factor-dependent procoagulant activity. Thromb Haemost 1998; 79: 1025-8.
• 23 Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Mullerberghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of EC. Nature 1998; 391: 591-4.
• 24 Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, Lawley TJ. HMEC-1 – Establishment of an Immortalized Human Microvascular Endothelial Cell Line. J Invest Dermatol 1992; 99: 683-9.
• 25 Mutin M, Dignat-George F, Sampol J. Immunologic phenotype of cultured endothelial cells: quantitative analysis of cell surface molecules. Tissue Antigens 1997; 50: 449-58.
• 26 Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphological and immunological criteria. J Clin Invest 1973; 52: 2745-56.
• 27 Poncelet P, George F, Lanza F. Quantitation of hematopoietic cell antigens by flow cytometry. Eur J Histochem 1996; 40: 15-32.
• 28 Lenich C, Liu J, Gurewich V. Thrombin stimulation of platelets induces plasminogen activation mediated by endogenous urokinase-type plasminogen activator. Blood 1997; 90: 3579-86.
• 29 Kahr WH, Zheng S, Sheth PM, Pai M, Cowie A, Bouchard M, Podor TJ, Rivard GE, Hayward PM. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001; 98: 257-5.
• 30 Lindemann S, Tolley ND, Dixon DA, McIntyre T, Prescott SM, Zimmerman GA, Weyrich AS. Activated platelets mediate inflammatory signaling by regulated interleukin 1b synthesis. J Cell Biol 2001; 154: 485-90.
• 31 Gurewich V, Johnstone M, Pannell R. The selective uptake of high molecular weight urokinase-type plasminogen activator by human platelets. Fibrinolysis 1995; 09: 188-19.